-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Avalo Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2015 to Q1 2025.
- Avalo Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was $8K, a 14.3% increase year-over-year.
- Avalo Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $114K, a 714% increase from 2023.
- Avalo Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $14K, a 50% decline from 2022.
- Avalo Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $28K, a 27.3% increase from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)